Log In
Print
BCIQ
Print
Print this Print this
 

Bexsero

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionMulti-component meningococcal serogroup B vaccine
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentMarketed
Standard IndicationMeningitis
Indication DetailsVaccinate against invasive meningococcal disease caused by serogroup B in people ages 10-25; Vaccinate against meningococcal disease
Regulatory Designation U.S. - Accelerated Approval (Vaccinate against invasive meningococcal disease caused by serogroup B in people ages 10-25);
U.S. - Breakthrough Therapy (Vaccinate against meningococcal disease);
EU - Standard Review (Vaccinate against meningococcal disease);
Australia - Standard Review (Vaccinate against meningococcal disease)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$7,100.0M

$5,300.0M

$1,800.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today